Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein

@article{Glaesner2010EngineeringAC,
  title={Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein},
  author={W. Glaesner and Andrew Mark Vick and R. Millican and B. Ellis and S. Tschang and Y. Tian and K. Bokvist and M. Brenner and A. Koester and N. Porksen and G. Etgen and T. Bumol},
  journal={Diabetes/Metabolism Research and Reviews},
  year={2010},
  volume={26}
}
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are novel agents for type 2 diabetes treatment, offering glucose‐dependent insulinotropic effects, reduced glucagonemia and a neutral bodyweight or weight‐reducing profile. However, a short half‐life (minutes), secondary to rapid inactivation by dipeptidyl peptidase‐IV (DPP‐IV) and excretion, limits the therapeutic potential of the native GLP‐1 hormone. Recently, the GLP‐1 receptor agonist exenatide injected subcutaneously twice daily… Expand
Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
TLDR
The aim of this review is to discuss the differences between and similarities of GLP‐1 RAs currently approved for clinical use, focusing particularly on the properties characterising the single short‐acting and long‐acting GLP'S receptor agonists rather than on their individual efficacy and safety profiles. Expand
A glycosylated Fc‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide
To evaluate the pharmacokinetic and pharmacodynamic properties of a novel glycosylated Fc‐fused glucagon‐like peptide‐1(GLP‐1‐gFc) receptor agonist with distinctive receptor binding affinity,Expand
The effects of LY2189265, a long‐acting glucagon‐like peptide‐1 analogue, in a randomized, placebo‐controlled, double‐blind study of overweight/obese patients with type 2 diabetes: the EGO study
Aim: To evaluate the efficacy and tolerability of once‐weekly LY2189265 (LY), a novel glucagon‐like peptide‐1 (GLP‐1) IgG4‐Fc fusion protein, in patients with type 2 diabetes failing oralExpand
GLP‐1 based therapies: differential effects on fasting and postprandial glucose
TLDR
It is proposed that these different GLP‐1‐mediated therapies are all necessary tools for the treatment of type 2 diabetes and that the choice of which one to use should depend on the specific needs of the patient. Expand
Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist
TLDR
Clinical Phase II and III trials show dose-dependent reductions of HbA1c up to 1.6%, reduction in fasting plasma glucose up to 2.7 mmol/l and weight reductions up to 3.2 kg. Expand
Synthesis and Evaluation of a Series of Long‐Acting Glucagon‐Like Peptide‐1 (GLP‐1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes
TLDR
GLP‐1 peptides conjugated to an ATIII binding carrier pentasaccharide have a substantially prolonged bioactive profile compatible for possible once‐weekly treatment of type 2 diabetes in humans. Expand
GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond
TLDR
The potential nonglycemic effects of GLP‐1 receptor agonists are examined, with liraglutide 3.0 mg day−1 approved for weight management and in the EU on March 23, 2015. Expand
An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future
TLDR
The once‐weekly GLP‐1 receptor analogues are promising candidates for the treatment of type 2 diabetes, although their efficacy may not be superior to once‐daily analogue liraglutide. Expand
Glutazumab, a novel long‐lasting GLP‐1/anti‐GLP‐1R antibody fusion protein, exerts anti‐diabetic effects through targeting dual receptor binding sites
TLDR
Glutazumab significantly bound and activated GLP‐1R, but the receptor antagonist exendin (9‐39) did not inhibit the activation except when combined with Ab1. Expand
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
TLDR
Together, this work determined the molecular basis for the activity of an oral agent being developed for the treatment of type 2 diabetes mellitus, offering insights into the activation of class B GPCRs by nonpeptide ligands. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor–Dependent Control of Glucose Homeostasis
TLDR
Taken together, the data demonstrate that CNTO736 produces a spectrum of GLP-1 receptor–dependent actions while exhibiting significantly improved pharmacokinetics relative to the native GLp-1 peptide. Expand
Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
TLDR
Findings demonstrate that an albumin-conjugated DAC:GLP-1 mimics the action of native GLP- 1 and represents a new approach for prolonged activation of GLP -1R signaling. Expand
A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.
TLDR
Findings illustrate that peripheral administration of a larger peptide-albumin recombinant protein mimics GLP-1R-dependent activation of central and peripheral pathways regulating energy intake and glucose homeostasis in vivo. Expand
Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
  • S. Madsbad
  • Medicine
  • Best practice & research. Clinical endocrinology & metabolism
  • 2009
TLDR
The GLP-1 analogues exenatide and liraglutide stimulate insulin secretion and inhibit glucagon output in a glucose-dependent manner, slow gastric emptying and decrease appetite, and the final place of the GLp-1 receptor agonists in the diabetes treatment algorithm will be clarified when they have long-term trials with cardiovascular end-points and data illustrating the effects on the progression of type 2 diabetes. Expand
Biology of incretins: GLP-1 and GIP.
This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic polypeptide (GIP)Expand
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
TLDR
It is concluded that DPP IV may be a primary inactivating enzyme of both GIP and tGLP-1 in vivo and reports of circulating hormone levels should be reconsidered. Expand
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
TLDR
Glucagon-like peptide 1 (GLP-1) could be a new treatment for type 2 diabetes, though further investigation of the long-term effects of this peptide hormone is needed. Expand
The incretin system and its role in type 2 diabetes mellitus
TLDR
The reduced incretin effect is believed to contribute to impaired regulation of insulin and glucagon secretion in T2DM, and, in support of this, exogenous GLP-1 administration may restore blood glucose regulation to near normal levels. Expand
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
TLDR
It is concluded that di peptidyl-peptidase IV initiates the metabolism of GIP and GLP-1(7-36)amide in human serum and inactivates these peptide hormones. Expand
Structural motifs involved in human IgG antibody effector functions
TLDR
The structural motifs underlying some of the documented differences in function between human (h) IgG1 and IgG4 forms of the antibody are defined, establishing an important role for the carboxy‐terminal half of the CH2 domain in determining differential behaviour in antibody‐dependent cytotoxicity (ADCC) and in complement lysis. Expand
...
1
2
3
...